Name: Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors (en Inglés)
SKU: 57663186
Price: 2747.85 MXN
Availability: InStock
Author: Pacak, Karel ; Taïeb, David
ISBN: 9783319460369

portada Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors (en Inglés)

Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors (en Inglés)

Formato

Libro Físico

Editorial

Humana

Autor

Pacak, Karel ; Taïeb, David

Idioma

Inglés

N° páginas

484

Encuadernación

Tapa Dura

Dimensiones

23.4x15.6x2.7 cm

Peso

0.87 kg.

ISBN13

9783319460369

N° edición

Categorías

Metabolismo
Radioterapia
Endocrinología
Medicina nuclear
Técnicas de diagnóstico por la imagen: radiología

Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors (en Inglés)

Pacak, Karel ; Taïeb, David (Autor) · Humana · Tapa Dura

Libro Nuevo Importado

Envío: 24 a 29 días háb.

$ 5,495.69$ 2,747.85

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 2,747.85

¡Envío Gratis! Llega entre el 07 Oct y el 15 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors (en Inglés)"

Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, andalpha radionuclide therapy, as well as the role of nanoparticles.Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.